A5063856648- Hormonal and reproductive studies
- Diabetes Treatment and Management
- Sexual function and dysfunction studies
- Health Systems, Economic Evaluations, Quality of Life
- Urinary Bladder and Prostate Research
- Pharmaceutical industry and healthcare
- Pancreatic function and diabetes
- Sexuality, Behavior, and Technology
- Diabetes Management and Research
- Pharmaceutical Economics and Policy
- Statistical Methods in Clinical Trials
- Pharmaceutical studies and practices
- Sexual Differentiation and Disorders
- Pharmacology and Obesity Treatment
- Growth Hormone and Insulin-like Growth Factors
- Patient-Provider Communication in Healthcare
- Medication Adherence and Compliance
- Retinal Imaging and Analysis
- Receptor Mechanisms and Signaling
- Lipid metabolism and disorders
- Genetic Syndromes and Imprinting
- Ethics in Clinical Research
- Healthcare Policy and Management
- Health Literacy and Information Accessibility
- Metabolism, Diabetes, and Cancer
Eli Lilly (United States)
2005-2017
Joslin Diabetes Center
2011
American Diabetes Association
2011
University of Kansas
2004
University of Arizona
2003
To test the safety and efficacy of exenatide once weekly (EQW) compared with metformin (MET), pioglitazone (PIO), sitagliptin (SITA) over 26 weeks, in suboptimally treated (diet exercise) drug-naive patients type 2 diabetes.Patients were randomized to subcutaneous (SC) EQW 2.0 mg + oral placebo (n = 248), MET 2,000 mg/day SC 246), PIO 45 163), or SITA 100 163) for weeks. therapies increased maximum-tolerated dosages. Injections administered weekly, while medication was daily.Baseline...
OBJECTIVE—Diabetes leads to protein kinase C (PKC)-β overactivation and microvascular dysfunction, possibly resulting in disordered skin blood flow (SkBF) other changes observed diabetic peripheral neuropathy (DPN) patients. We investigate the effects of isoform-selective PKC-β inhibitor ruboxistaurin mesylate on neurovascular function measures DPN. RESEARCH DESIGN AND METHODS—Endothelium-dependent fiber–mediated SkBF, sensory symptoms, neurological deficits, nerve fiber morphometry,...
In Brief Purpose: To evaluate efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with moderately severe to very nonproliferative diabetic retinopathy from the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2 ruboxistaurin (RBX) protein kinase inhibitor trials. Methods: Patients in these 3-year, randomized, placebo-controlled, double-masked, Phase 3 trials had best-corrected Early Treatment Diabetic visual acuity ≥45 letters (∼20/125 Snellen), level...
Context: Recombinant human GH was approved by the United States Food and Drug Administration in 2003 for treatment of idiopathic short stature (ISS). However, to date, safety this patient population has not been rigorously studied.
This study assessed the dose-dependent efficacy and safety of exenatide over 12 weeks in Japanese patients with type 2 diabetes suboptimally controlled despite therapeutic doses sulfonylurea (SU), SU plus biguanide, or thiazolidinedione. Patients were randomly assigned to placebo (N = 40), 2.5 μg 38), 5 37), 10 38) administered subcutaneously twice daily (BID). received BID for first 4 weeks, dose escalated final 8 weeks. 60.3 ± 9.7 years old, body mass index 25.3 4.3 kg/m2 hemoglobin A1c...
GH at 0.22 mg/kg.wk has been shown to have no effect on pubertal onset or pace, whereas 0.5 mg/kg x wk advance and bone maturation.Our objectives were determine whether 0.37 advanced onset, maturation relative 0.24 GH; led an inappropriately early age; age start of therapy influenced onset.We conducted a randomized, open-label study final height.We studied children with idiopathic short stature.Patients treated wk, increasing wk.We assessed rates maturation, Tanner stage development,...
This randomized, placebo-controlled, double-blind, parallel study assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly (QW) in 30 Japanese patients with type 2 diabetes (T2D) suboptimally controlled by diet exercise alone or combined biguanide, sulfonylurea, thiazolidinedione, combinations these agents (58.6% male; 58+/-9 years; body mass index 26.3+/-2.9 kg/m(2); hemoglobin A(1c) [HbA(1c)] 7.4+/-0.8%; fasting plasma glucose [FPG] 156.1+/-29.1...
This was a singledose, randomized, positive- and placebo-controlled, double-dummy, double-blinded, 3-period crossover thorough QT study of exenatide, glucagon-like peptide-1 receptor agonist for the treatment Type 2 diabetes that enhances insulin secretion in glucose- dependent fashion.Healthy subjects (n = 70) underwent an initial tolerability screening, receiving subcutaneous exenatide 10 μg daily 3 consecutive days. Subjects who passed screening 62) received μg, placebo, moxifloxacin (400...
This study evaluated pharmacokinetics, pharmacodynamics,safety, and tolerability of single doses exenatide in elderly Type 2 diabetes (T2D)patients.This placebo-controlled,patient-blind, crossover compared patients (≥ 75 y, n = 15) to controls( ≥ 45 ≤ 65y, with T2D. Patients were randomized subcutaneous 5μg, placebo or 10 μg (Sequence 1) placebo, 5 2) before a standardized breakfast over three consecutive days. Serial blood samples collected for plasma serum glucose...
This report describes patterns of treatment changes with the phosphodiesterase type 5 (PDE5) inhibitors tadalafil, sildenafil and vardenafil, variables associated those changes, during 6-month, prospective, pan-European Erectile Dysfunction Observational Study (EDOS).EDOS observed 8047 men > or = 18 years old erectile dysfunction (ED), who began changed ED therapy as part their routine healthcare. Patients could change at any time EDOS. Data were collected baseline 3 (+/- 1) 6 months....
Purpose: The purpose of this study was to provide quantitative evidence patients' tolerance for therapeutic risks associated with psoriasis treatments that could offer improvements beyond the PASI 75 benchmark.Materials and methods: We used a discrete-choice experiment in which respondents chose between competing characterized by benefits (i.e. reduced plaque severity, area), 10-year risk tuberculosis, death from infection), treatment regimen. analyzed choice data using random-parameters...
You have accessJournal of Urology1 Apr 2009ONCE-DAILY TADALAFIL IMPROVES ERECTILE FUNCTION IN MEN WITH BENIGN PROSTATIC HYPERPLASIA AND AN DYSFUNCTION HISTORY INDEPENDENT OF PROSTATE SIZE PRIOR α-BLOCKER USE Hartmut Porst, Kevin T McVary, Peter Sutherland, Albert Elion-Mboussa, Anne M Wolka, and Lars Viktrup PorstHartmut Porst More articles by this author , McVaryKevin McVary SutherlandPeter Sutherland Elion-MboussaAlbert Elion-Mboussa WolkaAnne Wolka ViktrupLars View All Author...